We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gene amplification and overexpression of HER2 in renal cell carcinoma.
- Authors
Latif, Z.; Watters, A.D.; Bartlett, J.M.S.; Underwood, M.A.; Aitchison, M.
- Abstract
Objective To determine the frequency of HER2 genetic abnormalities in renal cell carcinoma (RCC) and hence assess the potential suitability of Herceptin™ immunotherapy. Patients and methods Tumours from 27 patients with RCC were assessed; all patients had undergone nephrectomy. Benign renal tissue from the nephrectomy specimens was studied in seven patients. Gene amplification was assessed using fluorescent in-situ hybridization, and protein over-expression using immunohistochemistry. Results Twenty-four patients had clear cell renal carcinoma, two had papillary renal carcinoma and one a sarcomatoid variant carcinoma. There was no HER2 amplification in the tumours or the benign renal tissue. Polysomy 17 was detected in 11 of 27 tumours (41%) and increased HER2 copy number in seven (26%). Both polysomy 17 and increased HER2 copy number were absent in the benign renal tissue. Three tumours (11%) and six of the seven benign renal tissue samples over-expressed the HER2 protein. Conclusions HER2 amplification is absent and protein over-expression uncommon in RCC. This casts doubt on the suitability of Herceptin™ in the treatment of RCC.
- Subjects
GENE amplification; HER2 gene; RENAL cell carcinoma; CANCER treatment
- Publication
BJU International, 2002, Vol 89, Issue 1, p5
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1046/j.1464-410X.2002.02526.x